ArticleEating and weight disorders : EWD2025
Risk of hypermagnesemia in patients with eating disorders taking magnesium oxide preparations: a retrospective study.
Article in Eating and weight disorders : EWD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeThis study examined the incidence of hypermagnesemia in patients with eating disorders, its associations with renal function, body mass index, and magnesium oxide use, and the correlation between different methods of estimating renal function and serum magnesium levels.
methodsThis retrospective cohort study was conducted in female patients with eating disorders treated at Nagoya University Hospital between January 2018 and December 2022. Patients diagnosed as eating disorders, based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, were included. Serum magnesium levels, estimated glomerular filtration rate, body mass index, and magnesium oxide prescriptions were collected. Linear mixed-effects models were used to analyze factors affecting serum magnesium levels. Renal function screening methods were compared in underweight patients.
resultsAmong 194 patients, 42 (21.6%) developed hypermagnesemia (≥ 2.5 mg/dL; maximum 5.3 mg/dL). Younger age, lower body mass index, and reduced estimated glomerular filtration rate were linked to higher magnesium levels, whereas magnesium oxide use showed no clear association. Further analysis showed that the alternative estimated glomerular filtration rate method, adjusted for body size, negatively correlated with elevated serum magnesium levels in underweight patients.
conclusionThe incidence of hypermagnesemia in patients with eating disorders receiving magnesium oxide was comparable to previous studies. Risk factors include low body mass index, impaired renal function, and younger age. Although monitoring is warranted, severe complications were not observed, suggesting magnesium oxide need not be avoided. The use of body size-adjusted estimated glomerular filtration rate may improve the screening for hypermagnesemia in underweight patients. LEVEL OF EVIDENCE: Level III, well-designed cohort or case-control analytic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.